AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024.
Presentation Details
Conference: TD Cowen 44th Annual Health Care Conference
Format: Panel Discussion and 1x1 Meetings
Panel Topic: Novel IO Corporate Panel Discussion
- Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
- Date: March 4, ...